Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00540956|
Recruitment Status : Completed
First Posted : October 8, 2007
Last Update Posted : May 16, 2011
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: cytarabine Other: laboratory biomarker analysis||Not Applicable|
- Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
- Measure the kinetics of cytotoxic functional recovery of NK cells.
- Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Masking:||None (Open Label)|
|Official Title:||Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.|
|Study Start Date :||November 2006|
|Actual Primary Completion Date :||May 2011|
- Evolution of functional natural killer (NK) cells after chemotherapy
- Kinetics of NK cells
- Activation markers of NK cells
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00540956
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|OverallOfficial:||Norbert Vey, MD||Institut Paoli-Calmettes|